Iptacopan Achieves Primary Endpoint for Proteinuria Reduction in Patients with IgAN
Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.
Source: hcplive.com